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Abstract
Background:  Functional  constipation  and  irritable  bowel  syndrome  with  constipation  are  highly
prevalent and  affect  the  quality  of  life  of  those  who  suffer  from  them.
Aims: To  evaluate  quality  of  life  in  patients  with  functional  constipation  and  irritable  bowel
disease in  accordance  with  the  Rome  III  criteria,  using  the  PAC-QOL  and  SF-36  questionnaires.
Materials  and  methods:  A  cross-sectional  study  was  conducted  using  self-administered  ques-
tionnaires.  The  PAC-QOL,  SF-36,  and  Rome  III  constipation  module  questionnaires  were  applied
to patients  that  complained  of  constipation  at  the  outpatient  clinic  of  a  tertiary  care  hospital.
The constipation  subtypes  were:  functional  constipation  (no  pain),  irritable  bowel  syndrome
with constipation  (pain  and/or  discomfort  ≥  3  days/month),  and  unclassiﬁable  constipation
(pain ≤  2  days/month).  Data  were  summarized  in  proportions,  and  group  comparisons  were
made between  the  scores  of  each  of  the  areas  of  the  PAC-QOL  and  SF-36  questionnaires  using
parametric  tests  (Student’s  t  test  and  ANOVA).
Results:  A  total  of  43  PAC-QOL  surveys  were  analyzed,  resulting  in  cases  of  irritable  bowel  syn-
drome with  constipation  (14%),  functional  constipation  (37%),  and  unclassiﬁable  constipation
(49%). There  were  statistically  signiﬁcant  differences  (P  <  .05)  in  Physical  discomfort  (irritable
bowel syndrome  with  constipation  vs  functional  constipation  and  unclassiﬁable  constipation  vs
irritable bowel  syndrome  with  constipation),  Worries  and  concerns  (irritable  bowel  syndrome
with constipation  vs  functional  constipation),  and  Treatment  satisfaction  (irritable  bowel  syn-
drome with  constipation  vs  functional  constipation  and  unclassiﬁable  constipation  vs  irritable
bowel syndrome  with  constipation).  A  total  of  93  SF-36  questionnaires  were  analyzed,  describ-
ing cases  of  irritable  bowel  syndrome  with  constipation  (23%),  functional  constipation  (27%),
and unclassiﬁable  constipation  (51%).  Lower  physical  energy  was  found  in  relation  to  irritable
bowel syndrome  with  constipation  vs  functional  constipation  (P  <  .0221)  and  unclassiﬁable  con-
stipation (P  <  .0086),  respectively,  and  there  was  greater  physical  pain  in  the  cases  of  irritable
bowel syndrome  with  constipation  vs  unclassiﬁable  constipation  (P  <  .0362).
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Conclusions:  Differences  in  quality  of  life  of  patients  presenting  with  constipation  subtypes
were identiﬁed  using  the  PAC-QOL  and  SF-36  questionnaires.  The  patients  that  had  the  irritable
bowel syndrome  with  constipation  subtype  experienced  poorer  quality  of  life  in  all  the  evaluated
domains.
© 2014  Asociación  Mexicana  de  Gastroenterología.  Published  by  Masson  Doyma  México  S.A.  This
is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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a  los  criterios  de  ROMA  III
Resumen
Antecedentes:  El  estren˜imiento  funcional  y  el  síndrome  de  intestino  irritable  con  estren˜imiento
son altamente  prevalentes  y  generan  alteración  en  la  calidad  de  vida  de  quienes  los  padecen.
Objetivos:  Evaluar  la  calidad  de  vida  en  pacientes  con  estren˜imiento  funcional  y  síndrome  de
intestino  irritable,  de  acuerdo  a  los  criterios  de  ROMA  III,  utilizando  cuestionarios:  PAC-QOL  y
SF-36.
Materiales y  métodos: Estudio  transversal  tipo  encuesta  autoadministrado.  Se  aplicó  PAC-QOL,
SF-36 y  cuestionario  modular  de  estren˜imiento  ROMA  III  a  pacientes  con  queja  de  estren˜imiento
en la  consulta  externa  de  un  hospital  de  tercer  nivel.  Los  subtipos  de  estren˜imiento  fueron:
estren˜imiento funcional  (sin  dolor),  síndrome  de  intestino  irritable  con  estren˜imiento  (dolor
y/o malestar  ≥  3  días/mes)  y  estren˜imiento  no  clasiﬁcable  (dolor  ≤  2  días/mes).  Los  datos  se
resumen  en  proporciones,  y  se  realizaron  comparaciones  entre  la  puntuación  de  cada  uno  de
los rubros  de  ambos  cuestionarios  entre  los  grupos  utilizando  pruebas  paramétricas  (t-Student
y ANOVA).
Resultados:  Se  analizaron  43  encuestas  PAC-QOL,  síndrome  de  intestino  irritable  con
estren˜imiento  (14%),  estren˜imiento  funcional  (37%)  y  estren˜imiento  no  clasiﬁcable  (49%),  encon-
trándose diferencia  estadísticamente  signiﬁcativa  (p  <  0.05)  en  Malestar  físico  (síndrome  de
intestino irritable  con  estren˜imiento  vs.  estren˜imiento  funcional  y  estren˜imiento  no  clasiﬁcable
vs. síndrome  de  intestino  irritable  con  estren˜imiento),  Preocupaciones  (síndrome  de  intestino
irritable con  estren˜imiento  vs.  estren˜imiento  funcional)  y  Satisfacción  con  el  tratamiento  (sín-
drome de  intestino  irritable  con  estren˜imiento  vs.  estren˜imiento  funcional  y  estren˜imiento  no
clasiﬁcable vs.  síndrome  de  intestino  irritable  con  estren˜imiento).  Se  analizaron  93  encuestas
SF-36, síndrome  de  intestino  irritable  con  estren˜imiento  (23%),  estren˜imiento  funcional  (27%)
y estren˜imiento  no  clasiﬁcable  (51%),  encontrándose  menor  energía  física  entre  síndrome  de
intestino irritable  con  estren˜imiento  vs.  estren˜imiento  funcional  (p  <  0.0221)  y  estren˜imiento
no clasiﬁcable  (p  <  0.0086)  respectivamente,  y  mayor  dolor  físico  al  compararse  con  síndrome
de intestino  irritable  con  estren˜imiento  vs.  estren˜imiento  no  clasiﬁcable  (p  <  0.0362).
Conclusiones:  Utilizando  los  cuestionarios  PAC-QOL  y  SF-36  se  identiﬁcan  diferencias  en  la
calidad de  vida  en  los  subtipos  de  estren˜imiento.  Los  pacientes  con  la  variante  síndrome  de
intestino irritable  con  estren˜imiento  experimentan  menor  calidad  de  vida  en  todos  los  dominios
evaluados.
© 2014  Asociación  Mexicana  de  Gastroenterología.  Publicado  por  Masson  Doyma  México  S.A.
Este es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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unctional  constipation  (FC)  and  irritable  bowel  syn-
rome  (IBS)  are  2  diseases  that  present  frequently  in  the
opulation1 and  they  have  an  impact  on  the  quality  of  life
f  the  patients  that  suffer  from  them.2
The  prevalence  of  FC  has  been  estimated  at  5-25%
nd  a  recent  meta-analysis  has  calculated  it  at  14.4%
n  the  Mexican  population.3 The  worldwide  prevalence
f  IBS  is  from  10  to  20%  and  is  approximately  16%  in
exico.4
p
a
pPatients  with  chronic  disorders  not  only  suffer  from
hysical  pain,  but  they  are  also  affected  socially  and
sychologically.5 Patients  that  present  with  functional  gas-
rointestinal  disorders,  especially  FC  and  IBS,  have  been
hown  to  experience  poorer  quality  of  life.2 Several  studies
ave  demonstrated  these  ﬁndings,  particularly  in  patients
ith  an  FGID  that  present  with  moderate  to  severe  symp-
oms.  Lower  quality  of  life  scores  have  been  observed  in
atients  with  IBS,  when  compared  with  other  diseases  such
s  asthma,  and  similar  scores  have  been  reported  when  com-
ared  with  chronic  diseases.6
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iQuality  of  life  in  patients  with  different  constipation  subtyp
In  general,  constipation  has  an  important  impact  on  the
quality  of  life  of  those  that  present  with  it,  regardless  of
culture  or  nationality.  It  also  has  a  predominant  effect  in
areas  of  mental  health,  compared  with  other  chronic  condi-
tions  such  as  osteoarthritis  and  diabetes  mellitus.7
The  evaluation  of  quality  of  life  in  patients  with  FC
and  IBS  is  a  tool  through  which  the  effect  of  these  dis-
eases  on  physical  and  emotional  aspects  can  be  recognized.
Previous  studies  have  reported  that  these  disorders  cause
greater  school  and  work  absenteeism,  as  well  as  loss  of
productivity.2,8,9
Signiﬁcant  differences  in  the  physical  and  emotional
domains  of  the  SF-12  questionnaire  have  been  reported  in
patients  presenting  with  chronic  constipation,  when  com-
pared  with  subjects  that  do  not  have  this  problem.1 The
SF-36  questionnaire  has  been  used  in  different  studies
for  determining  overall  quality  of  life  in  patients  with  FC
and  IBS.  Statistical  differences  have  also  been  shown  in
all  the  domains  of  the  SF-36  between  IBS  patients  and
healthy  subjects,  in  each  of  the  8  scales  measured  by  this
tool.10
Due  to  the  prevalence  and  symptomatic  nature  of
chronic  constipation,  systematized  evaluations  are  par-
ticularly  important  in  order  to  have  better  long-term
understanding  and  management  of  these  patients.11
The  Patient  Assessment  of  Constipation-Quality  of  Life
(PAC-QOL)  is  a  28-item  questionnaire  that  has  recently  been
developed  for  the  speciﬁc  evaluation  of  quality  of  life  in
patients  presenting  with  constipation.11 It  has  been  used  to
assess  patients  with  constipation  in  phase  III  studies  that
have  been  carried  out  to  analyze  new  prokinetic  drugs  for
the  treatment  of  this  disorder.12
The  Rome  III  criteria  facilitate  the  diagnosis  of  func-
tional  gastrointestinal  disorders,  including  FC  and  IBS  with
constipation  (IBS-C).13 In  the  Rome  III  questionnaire  consti-
pation  module,  the  ﬁrst  question  is:  ‘‘In  the  last  3  months,
how  often  have  you  had  discomfort  or  pain  in  some  part
of  the  abdomen?’’  This  question  separates  the  two  prob-
lems  by  referring  to  the  presence  of  abdominal  discomfort  or
pain  and  the  answer  ranges  from  ‘‘Never’’  to  ‘‘Every  day’’.
According  to  the  answer,  it  is  possible  to  determine  whether
the  patient  has  FC  or  IBS-C.  However,  there  is  a  group  of
patients  that  presents  with  pain,  but  does  not  ﬁt  the  IBS
or  FC  criteria,  and  thus  they  are  described  as  patients  with
unclassiﬁable  constipation.
At  present,  there  is  no  study  that  analyzes  quality  of  life
with  both  general  and  speciﬁc  questionnaires  in  patients
with  constipation  and  its  different  subclassiﬁcations  based
on  the  Rome  III  criteria.  Therefore,  the  aim  of  our  study  was
to  evaluate  quality  of  life  in  patients  with  chronic  consti-
pation  and  its  variants  according  to  the  Rome  III  criteria
using  a  general  questionnaire  (SF-36)  and  a  speciﬁc  one
(PAQ-QOL).
Methods
PopulationA  cross-sectional  study,  employing  a  survey,  was  carried  out
within  the  time  frame  of  April  29  and  June  19,  2014.  Only
patients  complaining  of  constipation  that  were  encountered
e
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sased  on  the  Rome  III  criteria  15
n  the  waiting  room  of  the  outpatient  clinic  of  the  Internal
edicine  and  Gastroenterology  Departments  of  the  Instituto
acional  de  Ciencias  Médicas  y Nutrición  Salvador  Zubirán
ere  invited  to  participate.  The  study  was  approved  by  the
thics  Committee  of  the  Institute  and  all  patients  gave  state-
ents  of  informed  consent  before  taking  part  in  the  survey.
eﬁnitions
nitially,  the  Spanish  version  of  the  Rome  III  questionnaire
onstipation  module  was  applied  to  all  the  patients  that
ere  waiting  to  have  their  outpatient  consultation  and
hat  answered  the  question  ‘‘Do  you  suffer  from  consti-
ation?’’  afﬁrmatively.  Afterwards  the  Spanish  versions  of
he  self-administered  PAC-QOL  and  SF-36  version  2  question-
aires  were  applied.
Constipation  was  considered  to  be  present  if  the  patient
ad  2 of  the  following  6  Rome  III  constipation  symptoms:
)  straining  during  at  least  25%  of  defecations,  2)  lumpy
tools  in  at  least  25%  of  defecations,  3)  sensation  of  incom-
lete  evacuation  in  at  least  25%  of  defecations,  4)  sensation
f  anorectal  obstruction/blockage  in  at  least  25%  of  defe-
ations,  5)  manual  maneuvers  to  facilitate  at  least  25%  of
efecations,  and  6)  bowel  movements  ≤  3  times  a  week.
atients  were  regarded  as  having  constipation  if  they  pre-
ented  with  2  of  these  6  symptoms  and  if  symptom  onset
as  ≥  6 months.
According  to  the  answer  to  the  ﬁrst  question  of  the
ome  III  constipation  module,  ‘‘In  the  last  3  months,  how
ften  have  you  had  discomfort  or  pain  in  some  part  of  the
bdomen?’’,  the  patients  were  classiﬁed  as  follows:  1)  FC,
f  the  answer  was  ‘‘0’’  (‘‘Never’’)  in  addition  to  having  2  or
ore  of  the  6  constipation  symptoms,  2)  IBS-C,  if  the  answer
as  ‘‘≥  3’’  (presence  of  abdominal  discomfort  or  pain  ‘‘2
r  3  days  a  month’’,  ‘‘Once  a  week’’,  ‘‘More  than  once  a
eek’’,  or  ‘‘Every  day’’)  and  the  presence  of  2  or  more  of
he  6  constipation  symptoms,  and  3)  unclassiﬁable  constipa-
ion,  if  the  answer  was  ‘‘1  and  2’’  (presence  of  abdominal
iscomfort  or  pain  ‘‘Less  than  once  a month’’,  or  ‘‘Once  a
onth’’),  without  meeting  the  criteria  for  IBS  or  FC,  but  hav-
ng  at  least  2  of  the  6  constipation  symptoms.  Figure  1  shows
 ﬂow  diagram  that  explains  the  questionnaire  application
rocess  in  the  patients  with  constipation.
uality  of  life  (PAC-QOL  and  SF-36)
he  PAC-QOL  questionnaire  consists  of  28  items  grouped
nto  4  subscales:  a)  Physical  Discomfort,  b)  Psychosocial
iscomfort,  c)  Worries  and  Concerns,  and  d)  Treatment  Sat-
sfaction.  Scoring  was  done  on  a  Likert  5-point  scale  from  0
Nothing/Never)  to  4  (Extremely/Always)  in  which  a  lower
core  reﬂected  a better  quality  of  life.11
The  SF-36  questionnaire  evaluates  quality  of  life  in  adult
opulations  (above  16  years  of  age)  and  is  made  up  of
6  items  that  assess:  a)  Physical  Function,  b)  Physical  Lim-
tation,  c)  Emotional  Limitation,  d)  Emotional  Well-being,
)  Bodily  Pain,  f)  Fatigue/Energy,  g)  Social  Function,  and
)  General  Health.  Each  subscale  has  a  score  from  0  to  100,
n  which  the  higher  score  is  equivalent  to  a  better  health
tatus.14,15
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Rome III questionnaires
applied
n=101
PAC-QOL questionnaires
applied
n=48
Excluded
n=5
Incomplete questionnaires
n=5
Questionnaires analyzed
n=43
Questionnaires analyzed
n=93
SF-36 questionnaires
applied
n=101
Incomplete questionnaires
n=3
Withdrew consent
n=5
Excluded
n=8
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From  the  total  number  of  PAC-QOL  questionnaires
pplied,  5  were  eliminated  because  they  were  incomplete
nd  from  the  total  of  the  SF-36  questionnaires  applied,  8
ere  eliminated;  3  because  they  were  incomplete  and  5
ecause  the  participant  withdrew  his  or  her  consent  to  par-
icipate  in  the  study  (ﬁg.  1).
tatistical  analysis
he  continuous  variables  were  summarized  as  means  and
he  categorical  variables  as  percentages.  The  different
onstipation  subtype  scores  were  compared  through  para-
etric  statistics  for  each  of  the  areas  of  the  PAC-QOL
nd  SF-36  questionnaires  (Student’s  t  test  and  ANOVA),
sing  the  GraphPad  Prism  Version  5.03  statistical  pack-
ge.
esults
 total  of  101  patients  answered  the  Rome  III  questionnaire
onstipation  module  for  constipation  diagnosis.  Figure  1
hows  the  number  of  PAC-QOL  and  SF-36  questionnaires
pplied.  The  mean  length  of  time  it  took  to  answer  the  3
uestionnaires  was  25  min.  A  total  of  101  questionnaires
ere  applied  and  the  patient  age  range  was  from  18  to
a
1
s
(
Table  1  Demographic  characteristics  of  the  patients,  according  
pation, functional  constipation,  and  unclassiﬁable  constipation.
Irritable  bowel  sy
with  constipation
n  =  21
Age
Mean,  interval  42.8  years  (20-70  
Sex
Women 20  (95.23%)  
Men 1  (4.76%)  
Comorbidities
None 5  (23.8%)  
Diabetes mellitus  0  (0%)  
High blood  pressure  2  (9.52%)  
Hypothyroidism  3  (14.28%)  
Diabetes mellitus  +  high  blood  pressure  6  (28.57%)  
Others 5  (23.8%)  ires  that  were  applied  and  analyzed.
7  years  (a  mean  of  48.72);  77  were  women  and  16  were
en.  Table  1  shows  the  demographic  data.
Patient  Assessment  of  Constipation-Quality  of  Life  (PAC-
OL)
A  total  of  43  questionnaires  were  analyzed.  The  female
ex  was  predominant  (91%)  in  the  study  population  and  the
ean  age  was  51  years  (range:  20-87).  The  groups  were
istributed  as  follows,  based  on  the  Rome  III  criteria:  IBS-
 (14%),  FC  (37%),  and  unclassiﬁable  constipation  (49%)
ﬁg.  2).
hysical  Discomfort
he  analysis  between  groups  showed  signiﬁcant  differ-
nces  (p  =  0.0299).  Upon  comparing  individual  groups,  the
BS-C  group  had  a  higher  score,  compared  with  the  FC
roup  (p  =  0.0029;  10.00  ±  1.125  vs  4.938  ±  0.8086)  and  the
nclassiﬁable  constipation  group  (p  =  0.0369,  10.00  ±  1.125
s  5.727  ±  0.9584)  (ﬁg.  3).
sychosocial  Discomfort
n  relation  to  psychosocial  discomfort,  the  IBS-C  group  had higher  score  compared  with  the  FC  group  (p  =  0.0278;
4.33  ±  2.704  vs  7.438  ±  1.469)  and  the  unclassiﬁable  con-
tipation  group  (p  =  0.0405,  14.33  ±  2.704  vs  6.818  ±  1.658)
ﬁg.  3).
to  the  groups  studied:  irritable  bowel  syndrome  with  consti-
ndrome Functional
constipation
n  =  25
Unclassiﬁable
constipation
n  =  47
years)  51.05  years
(18-69  years)
49.7  years
(18-87  years)
19  (76%)  38  (80.85%)
6  (24%)  9  (19.14%)
9  (36%)  14  (29.78%)
0  (0%)  2  (4.25%)
0  (0%)  4  (8.51%)
1  (3.6%)  4  (8.51%)
11  (44%)  13  (27.65%)
4  (16%)  10  (21.27%)
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Rome III criteria
b  PAC-QOLa  SF-36
IBS-C Unclassifiable constipationFC
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23%
27%
49%
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SFigure  2  Distribution  of  the  patients  that  answered  the  a)  SF
FC: functional  constipation;  IBS-C:  irritable  bowel  syndrome  wi
Worries  and  Concerns
Likewise,  there  were  signiﬁcant  differences  upon  comparing
the  IBS-C  group  with  the  FC  group  (p  =  0.0379;  17.33  ±  4.410
vs  9.375  ±  1.494),  but  there  was  no  signiﬁcant  difference
between  the  unclassiﬁable  constipation  group  and  the  IBS-C
and  FC  groups  (p  >  0.05)  (ﬁg.  3).
Treatment  Satisfaction
There  was  a  difference  in  the  degree  of  treatment  satisfac-
tion  among  the  3  groups  (p  =  0.0443).  The  patients  with  IBS-C
had  a  higher  score  compared  with  those  with  FC  (p  =  0.0180;
16.50  ±  0.4282  vs  10.31  ±  1.440),  as  well  as  with  the  patients
with  unclassiﬁable  constipation  (p  =  0.0305;  16.50  ±  0.4282
vs  11.77  ±  1.059)  (ﬁg.  3).
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verall  PAC-QOL
here  was  a  difference  between  groups  in  relation  to  the
otal  score.  There  was  also  a  difference  when  comparing
he  IBS-C  and  FC  patients  (p  =  0.0034;  2.077  ±  0.2704  vs
.146  ±  0.1391)  and  the  IBS-C  and  unclassiﬁable  constipa-
ion  patients  (p  =  0.0440;  2.077  ±  0.2704  vs  1.323  ±  0.1699)
ﬁg.  3).
F-36  questionnaire total  of  93  questionnaires  were  analyzed.  The  female  sex
redominated  (82%)  in  the  study  population  and  the  mean
ge  was  48.70  years  (range:18-87).  In  accordance  with  the
ome  III  criteria,  the  groups  were  distributed  as  follows:
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BS-C  (23%),  FC  (27%),  and  unclassiﬁable  constipation  (51%)
ﬁg.  2).
hysical  Function,  Physical  Limitation,  Emotional
ell-Being,  Social  Function,  and  General  Health
here  were  no  statistically  signiﬁcant  differences  (p  >  0.05)
etween  the  IBS-C,  FC,  and  unclassiﬁable  constipation
roups  during  the  analysis  (ﬁg.  4).
ody  Pain
here  was  no  signiﬁcant  difference  among  the  3  groups,
ut  there  was  a  difference  between  the  IBS-C  group  and
nclassiﬁable  constipation  group  (p  =  0.0362,  49.64  ±  5.290
s  63.62  ±  3.673),  indicating  that  patients  with  IBS-C  expe-
ience  more  physical  pain  than  those  with  unclassiﬁable
onstipation  (ﬁg.  4).
atigue/Energy
here  was  a  statistically  signiﬁcant  difference  between  the
 groups  (p  =  0.0255).  A  signiﬁcant  difference  was  found
pon  comparing  the  IBS-C  group  and  the  FC  group
41.67  ±  3.386  vs  55.20  ±  4.383,  p  =  0.0221),  signifying  that
he  patients  with  IBS-C  experience  a  lower  energy  level
han  those  with  FC.  A  difference  was  also  found  when  IBS-C
atients  were  compared  with  the  unclassiﬁable  constipa-
ion  patients  (41.67  ±  3.386  vs  54.01  ±  2.641,  p  =  0.0086)
ﬁg.  4).
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ur  study  showed  that  there  are  differences  in  the  Rome
II-based  constipation  subtypes  in  terms  of  quality  of  life,
valuated  using  both  speciﬁc  and  general  questionnaires.
ccording  to  the  SF-36  questionnaire,  the  patients  with  IBS-C
ere  shown  to  be  the  most  affected  group,  when  com-
ared  with  those  of  the  FC  and  unclassiﬁable  constipation
roups,  even  though  the  differences  were  in  only  a  few
spects.  With  respect  to  the  PAC-QOL  questionnaire,  the  IBS-
 patients  showed  a  poorer  quality  of  life,  followed  by  the
atients  in  the  unclassiﬁable  constipation  group  and  the  FC
roup.
Ours  is  the  ﬁrst  study  conducted  on  a  Mexican  population
hat  evaluates  quality  of  life  both  generally  and  speciﬁcally
n  subgroups  based  on  the  Rome  III  criteria.
Previous  studies  have  shown  that  patients  with  gastroin-
estinal  disorders,  mainly  IBS  and  FC,  present  with  a  poorer
uality  of  life,2 regardless  of  culture  or  nationality.  This
s  especially  true  in  regard  to  older  adults7 and  is  related
o  symptom  severity,  being  more  evident  in  patients  with
oderate  or  severe  symptoms.6
Much  attention  has  been  paid  to  quality  of  life  by
esearchers  and  therapists  because  it  allows  the  impact  a
isease  has  on  different  spheres  of  patient  life  to  be  known,
ith  a  consequent  understanding  of  the  patient’s  percep-
ions  in  relation  to  his  or  her  environment.  Therefore  it  is
f  interest  to  evaluate  quality  of  life  in  order  to  determine
reatment  improvement  and  progress  and  to  establish  their
bscales
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in  (BP),  Emotional  Limitation  (EL),  Emotional  Well-being  (EW),
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fQuality  of  life  in  patients  with  different  constipation  subtyp
level  of  impact  on  the  physical,  mental,  and  social  realms
of  the  individuals  presenting  with  these  diseases.5
Patients  with  chronic  constipation  have  a  poorer  qual-
ity  of  life  compared  with  healthy  subjects.  Moreover,  there
are  reports  indicating  that  patients  with  IBS  experience
diminished  vitality.16 Using  the  SF-12,  statistically  signif-
icant  differences  were  found  between  the  physical  and
mental  components  of  patients  with  chronic  constipation,
compared  with  healthy  subjects.  However,  no  differences
were  found  with  the  application  of  the  Quality  of  Life
in  Constipation-20  (CVE-20)1 questionnaire  that  speciﬁcally
assesses  quality  of  life  in  patients  with  constipation.
Patients  with  IBS  experience  physical,  emotional,  and
social  symptoms  that  have  a  negative  impact  on  quality  of
life.  IBS  treatment  is  directed  at  relieving  the  symptoms  and
improving  the  functioning  of  the  subjects  that  present  with
this  disorder,  making  the  use  of  scales  for  measuring  quality
of  life  relevant.17
It  has  been  demonstrated  that  patients  with  FC  expe-
rience  a  diminished  quality  of  life,  comparable  to  that
of  patients  presenting  with  diseases  such  as  asthma  and
rheumatoid  arthritis.18 Using  the  SF-36  questionnaire,  IBS
patients  have  been  shown  to  have  lower  scores  than  a  sample
of  healthy  subjects  in  a  United  States  population.17 Similar
results  have  been  reported  in  European  studies  comparing
IBS  patients  with  healthy  volunteers.19
Quality  of  life  in  patients  with  IBS  and  FC  appears  to
improve  in  those  patients  that  respond  to  any  given  treat-
ment  that  is  correlated  with  symptom  improvement.  There
are  factors  that  are  apparently  related  to  the  quality  of  life
experienced  by  the  patients,  and  they  include  psychosocial
elements,  pain,  and  chronic  stress.6 Decreased  quality  of
life  can  result  in  school  and  work  absenteeism  and  can  also
reduce  productivity.2,8,9
Our  study  has  several  limitations.  Given  that  the  ques-
tionnaires  are  self-administered,  it  is  possible  that  the
patient  may  not  adequately  understand  a  question,  depend-
ing  on  his  or  her  educational  level,  sociocultural  situation,
or  interest  or  motivation  in  ﬁlling  out  the  questionnaire.12,20
In  addition,  our  sample  was  small  and  perhaps  was  biased
due  to  the  fact  that  the  questionnaires  were  applied  at
a  tertiary  care  center.  Likewise,  the  type  of  study  (cross-
sectional)  does  not  permit  the  corroboration  of  constipation
pathophysiology  through  auxiliary  studies  and  the  group  of
patients  analyzed  were  seen  at  the  outpatient  clinic  of  a  ter-
tiary  care  hospital  and  thus  might  present  with  more  intense
symptomatology;  both  of  these  situations  could  inﬂuence
the  results.  There  could  also  have  been  bias  in  the  selec-
tion  of  our  patients,  because  the  questionnaires  were  only
administered  to  those  patients  thought  to  be  ‘‘constipated’’
and  that  upon  analyzing  the  answers  in  the  Rome  III  ques-
tionnaire  constipation  module  they  were  found  to  meet  the
criteria  for  being  classiﬁed  as  having  IBS  and/or  constipa-
tion.  Nevertheless,  the  aim  of  the  study  was  to  analyze
quality  of  life  in  a  population  presenting  with  constipation
and  therefore  we  exclusively  directed  the  questionnaires  to
such  a  population.
Quality  of  life  in  the  patients  that  complained  of  con-
stipation  was  initially  evaluated  through  the  general  SF-36
questionnaire,  after  which  the  speciﬁc  PAC-QOL  question-
naire  was  added  to  the  analysis.  The  number  of  patients
that  answered  the  latter  was  lower  and  so  we  felt  it  was
D
f
tased  on  the  Rome  III  criteria  19
ecessary  to  increase  the  number  of  measurements  for  that
uestionnaire.  Likewise,  since  it  was  as  speciﬁc  question-
aire  for  the  population  with  constipation  we  did  not  apply
his  type  of  questionnaire  to  a  healthy  population.
However,  as  study  strengths,  we  believe  that  the  patient
ould  answer  the  PAC-QOL  and  SF-36  items  with  greater  sin-
erity.  The  use  of  self-administered  questionnaires  enables
nformation  on  sensitive  subjects  (situations  that  cause
mbarrassment)  to  be  approached  with  greater  accuracy
nd  conﬁdentiality20--important  advantages  in  this  study.
he  sample  was  an  open  one,  not  selected  by  speciality  or
y  disease.  The  patients  that  were  waiting  for  their  medi-
al  consultation  were  not  necessarily  there  because  of  their
onstipation,  but  rather  for  other  factors,  which  is  why  we
eel  there  was  a  lower  level  of  ultra-selection  of  the  sample.
In  general  the  questionnaires  were  well  received;  the
atients  responded  without  pressure  and  the  quality  of  their
utpatient  medical  attention  was  in  no  way  affected  by
hether  or  not  they  participated  in  the  study.
The  difference  observed  in  how  quality  of  life  was
ffected  utilizing  the  different  questionnaires  was  interest-
ng  and  is  probably  related  to  the  fact  that  the  PAC-QOL
s  a  tool  that  is  used  speciﬁcally  in  patients  with  consti-
ation,  whereas  the  SF-36  evaluates  general  aspects  of  an
ndividual’s  health.
When  quality  of  life  is  affected,  its  impact  on  the  devel-
pment  of  patients  in  terms  of  productivity,  absenteeism,
nd  presenteeism  is  not  known.  Constipation  treatment
mproves  the  quality  of  life  of  the  subjects,6,21 but  it  is  not
nown  whether  their  work  productivity  or  general  welfare
s  also  improved.  And  ﬁnally,  it  appears  that  there  are  other
actors  beyond  abdominal  pain  that  inﬂuence  the  worsening
f  quality  of  life  in  subjects  with  IBS  that  need  to  be  identi-
ed  in  order  to  implement  strategies  targeted  at  improving
hem  for  the  well-being  of  these  patients.
onclusions
he  SF-36  questionnaire  demonstrated  that  the  patients
ith  IBS-C  had  a  poorer  quality  of  life,  compared  with  the  FC
roup  and  the  unclassiﬁable  constipation  group.  There  were
tatistically  signiﬁcant  differences  in  speciﬁc  areas  related
o  fatigue/energy  and  the  presence  of  pain.
The  PAC-QOL  questionnaire,  which  is  speciﬁcally  for
atients  with  constipation,  showed  differences  in  the
atients  with  constipation  subtypes;  the  patients  with  IBS-C
ere  the  most  affected,  compared  with  the  other  subtypes.
urther  studies  are  needed  to  determine  the  impact  on  per-
ormance  in  different  productive  areas  (productivity,  absen-
eeism,  etc.)  when  quality  of  life  is  affected  in  patients  that
resent  with  the  different  constipation  subtypes.
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